Current role
Biotechnology · Healthcare
Chief Accounting Officer
2022-03-17–present
Jonathan Alspaugh
Chief Accounting Officer
Spyre Therapeutics, Inc. (SYRE)Equibles does not estimate personal net worth.
Get an email with a short summary when Spyre Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SYRE alertsAbout Jonathan Alspaugh
Jonathan Alspaugh is recorded as Chief Accounting Officer at Spyre Therapeutics, Inc. (SYRE) since March 17, 2022. The proxy statement of Spyre Therapeutics, Inc. reports total compensation of $8,360,029 for Jonathan Alspaugh in fiscal 2023, including a base salary of $329,767. Disclosed compensation is on record for 2 fiscal years. Spyre Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Spyre Therapeutics, Inc. includes Cameron Turtle (CEO, COO and Board Member), Cameron Turtle, DPhil (CEO and Board Member), James Kastenmayer (CEO) and 7 others.
Affiliation history
-
Current
2022-03-17–present
-
Start not stated–2024-04-01
Last confirmed by a filing; no departure on record
-
Start not stated–2023-09-01
Company network
Leadership on record at Spyre Therapeutics, Inc.
- Cameron Turtle CEO, COO, Board Member
- Cameron Turtle, DPhil CEO, Board Member
- James Kastenmayer CEO
- Jeffrey M. Goldberg CEO
- Scott Burrows CFO, Chief Accounting Officer
- Heidy Abreu King-Jones General Counsel
- Steven Weber Chief Accounting Officer
- Jeffrey Albers Board Member
- Laurie Stelzer Board Member
- Mark McKenna Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Spyre Therapeutics, Inc. (SYRE) | Former Chief Financial Officer | $329,767 | $8,360,029 |
| 2022 | Spyre Therapeutics, Inc. (SYRE) | Former Chief Financial Officer | $425,001 | $1,011,840 |
Recent activity
No call appearances or filed executive changes recorded yet.